Mounjaro and Zepbound are the same active drug — tirzepatide — from the same maker, approved and labeled for different uses. Here’s a neutral rundown of how they differ. This is educational, not medical advice; which one fits you is a prescriber’s call.
| Mounjaro | Zepbound | |
|---|---|---|
| Active drug | Tirzepatide | Tirzepatide |
| FDA-approved use | Type 2 diabetes | Chronic weight management (and obstructive sleep apnea) |
| Dose ladder | 2.5 to 15 mg weekly | 2.5 to 15 mg weekly |
Because they’re approved for different conditions, insurance coverage often differs, and you can’t swap one for the other on your own. A prescriber decides which product fits your situation.
A diabetes drug and a weight-management drug are frequently covered differently — see ways people lower GLP-1 costs (informational, no vendor picks).
Yes — both are tirzepatide from the same maker. They differ in FDA-approved use and labeling.
Zepbound is approved for chronic weight management (and obstructive sleep apnea); Mounjaro is approved for type 2 diabetes.
Not on your own. Any switch is a decision for your prescriber, even though the active drug is the same.
Often yes — plans cover a diabetes drug and a weight-management drug differently, so the same molecule can be covered under one label and not the other.
They share tirzepatide’s side-effect profile. Experiences vary by person and dose.